Abstract | OBJECTIVE: To follow-up on all available infliximab-treated SLE patients for safety and long-term efficacy in order to extract information that is useful for planning appropriate controlled trials with infliximab in SLE. METHODS: We analysed charts of six patients treated in an open-label safety trial and seven additional patients treated with infliximab on a compassionate care basis for uncontrolled SLE organ inflammation. RESULTS: Out of nine patients with lupus nephritis, six had a long-term response after four infusions of infliximab in combination with AZA, lasting for up to 5 years. All five patients with lupus arthritis responded, but this response did not last for >2 months after the last infusion. One additional patient had a long-lasting improvement in SLE interstitial lung disease. No symptoms suggestive of infliximab-induced SLE flares occurred in any patients. Short-term treatment appeared relatively safe, but one patient developed deep-vein thrombosis and several infections. Under long-term therapy, two patients had life-threatening or fatal events, namely CNS lymphoma and Legionella pneumonia. Retreatment and treatment without concomitant immunosuppression led to drug reactions. CONCLUSIONS:
|
Authors | Martin Aringer, Frederic Houssiau, Caroline Gordon, Winfried B Graninger, Reinhard E Voll, Eva Rath, Guenter Steiner, Josef S Smolen |
Journal | Rheumatology (Oxford, England)
(Rheumatology (Oxford))
Vol. 48
Issue 11
Pg. 1451-4
(Nov 2009)
ISSN: 1462-0332 [Electronic] England |
PMID | 19748965
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Antibodies, Monoclonal
- Antirheumatic Agents
- Immunosuppressive Agents
- Tumor Necrosis Factor-alpha
- Infliximab
- Azathioprine
|
Topics |
- Adult
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antirheumatic Agents
(adverse effects, therapeutic use)
- Azathioprine
(adverse effects, therapeutic use)
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Humans
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Infliximab
- Lung Diseases, Interstitial
(drug therapy)
- Lupus Erythematosus, Systemic
(drug therapy)
- Lupus Nephritis
(drug therapy)
- Male
- Middle Aged
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|